Efficacy and safety of prasugrel in acute coronary syndrome patients
Radu M Nanau1, Faustine Delzor2, Manuela G Neuman1
1In Vitro Drug Safety and Biotechnology, Toronto, ON, Canada; Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Insights
Prasugrel effectively inhibits platelets to prevent ischemic events in heart disease patients. However, its use involves a careful balance between reducing cardiovascular risks and managing bleeding complications and other adverse reactions.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ischemic heart disease (IHD) is a leading global cause of mortality.
- Cardiovascular disease pathogenesis involves atheromatous plaque formation and rupture, leading to thrombosis.
- Platelet inhibitors are crucial for preventing thrombosis in IHD patients.
Purpose of the Study:
- To systematically review the efficacy of prasugrel.
- To evaluate prasugrel's platelet inhibition and clinical outcomes.
- To assess the benefit-risk balance, including bleeding risk and other adverse events.
Main Methods:
- Systematic review of clinical studies.
- Analysis of prasugrel's antiplatelet activity.
- Evaluation of cardiovascular event reduction and bleeding incidence.
Main Results:
- Prasugrel demonstrates significant potential in platelet inhibition.
- The drug is effective in preventing ischemic cardiovascular events.
- Bleeding risk and other adverse events, including hematological, cutaneous, hepatic, and potential cancer promotion, require careful consideration.
Conclusions:
- Prasugrel is an effective antiplatelet agent for managing ischemic heart disease.
- Clinical use necessitates a thorough risk-benefit assessment, balancing ischemic event reduction against bleeding and other adverse effects.
- Further research into the complex relationship between prasugrel and cancer promotion is warranted.
Abstract:
Ischemic heart disease is the primary cause of death worldwide. The pathophysiological process of cardiovascular diseases is linked to atheromatous plaque formation, while plaque rupture releases thrombogenic elements, which lead to activation of platelets, blood clotting and formation of thrombi. Platelet inhibitors are used to prevent thrombosis. The present systematic review discusses the efficacy of prasugrel in terms of platelet inhibition potential and clinical prevention of cardiovascular outcomes. The balance between reduction of ischemic events as a measure of drug efficacy and the risk of bleeding is reviewed. Other adverse events observed in patients treated with this platelet inhibitor are discussed, including hematological complications, and cutaneous and hepatic idiosyncratic reactions. The complex relationship between prasugrel use and cancer promotion is also described.
More Related Videos
10:28Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Acute Coronary Syndrome I: Introduction
01:27Coronary Artery Disease V: Interprofessional Care
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations